Integration of chemotherapy and radiation is the standard practice in the management of locally advanced inoperable @entity1149 . To assess the biological interaction between third generation chemotherapeutic agents and radiation in @entity1149 ( @entity1149 ) in vitro, we tested a number of different drugs ( @entity1311 , @entity1205 , @entity136 , @entity1945 , @entity2600 and @entity900 ) combined with radiation, in @entity2 cell lines. Cellular chemosensitivity was determined, using the semi-automated colorimetric @entity98 assay, after 48, 72 and 96 h of exposure to increasing drug concentrations, (0.001-100 microM) and radiation doses (100-400 cGy). Cell lines used were the @entity420 ( @entity20946 ), A-549, and the @entity957 ( @entity957 ), LX-1. Cells were pre-treated with anticancer agents at 24, 12 and 0 h before irradiation. Cytofluorimetric cell cycle analysis was performed. A significant S-phase block or a G(2)/M block was seen with @entity136 and @entity1945 or @entity1311 pre-treatment, respectively. Apoptosis was seen only after @entity1311 exposure in the A-549 cell line. Despite a similar pattern of cell-kinetic changes induced by chemotherapy pre-treatment in all cell lines, the @entity420 A-549 cell line was not radiosensitized by any of the anticancer agents tested, whereas synergism was observed in the LX-1 @entity957 cell line, when exposed to @entity136 , @entity2600 , @entity1945 and @entity900 . @entity1311 , despite a favourable cell cycle effect, was not found to be synergistic with radiotherapy in our experimental model. In conclusion, the observed synergism appears to be dose- and timing-independent and seems to be related to the histological subtype being present in @entity957 only. Favourable perturbation of the cell cycle is evident with all the new agents tested in both cell types, but was not sufficient to produce synergism with radiation.

Interaction between novel anticancer agents and radiation in XXXX cell lines.

@entity20946 :: ('132', 'Gene') :: ['ADK'] @entity2600 :: ('MESH:C051890', 'Chemical') :: ['SN-38'] @entity957 :: ('MESH:D002294', 'Disease') :: ['squamous-cell carcinoma', 'SCC', 'squamous carcinoma'] @entity1149 :: ('MESH:D002289', 'Disease') :: ['NSCLC', 'non-small cell lung cancer'] @entity1311 :: ('MESH:D017239', 'Chemical') :: ['paclitaxel', 'Paclitaxel'] @entity900 :: ('MESH:D002945', 'Chemical') :: ['cisplatin'] @entity2 :: ('MESH:D008175', 'Disease') :: ['lung cancer'] @entity420 :: ('MESH:D000230', 'Disease') :: ['adenocarcinoma'] @entity136 :: ('MESH:C056507', 'Chemical') :: ['gemcitabine'] @entity98 :: ('CHEBI:53233', 'Chemical') :: ['MTT'] @entity1205 :: ('MESH:C067311', 'Chemical') :: ['docetaxel'] @entity1945 :: ('MESH:D019772', 'Chemical') :: ['topotecan']
@entity1149 :: (MESH:D002289,Disease) :: ['non-small cell lung cancer']
